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Carbohydrate antigen 19-9 (CA 19-9) is the carbohydrate Villano et al., 1983). To ensure that the normal range was
determinant (sialylated lacto-N-Fucopentaose II) of a the same in Blacks, serum from 30 apparently healthy Black
circulating antigen which was detected originally, using a subjects matched with the HCC patients for age and sex was
monoclonal antibody, in the cell membrane of a human assayed.
colon carcinoma growing in cell culture (SWI 116) Serum CA 19-9 and AFP concentrations were measured in
(Koprowski et al., 1981; Magnani et al., 1982; 1983). Raised sera which had been obtained by peripheral venesection,
serum values of the antigen have been found in patients with separated and frozen within 2h, and stored at -20°C. In the
a variety of gastrointestinal tumours, particularly pancreatic case of the cancer patients, serum was obtained for assay
carcinoma, in which a sensitivity for CA 19-9 of 70% or before cancer chemotherapy was begun. CA 19-9 values were
more has consistently been reported (Koprowski et al., 1981; measured by solid-phase sandwich radioimmunoassay
Del Villano et al., 1983; Kuusela et al., 1984; Jalanko et al., (Centocor Co., Malvern, PA). AFP was measured by radio-
1984; Satake et al., 1985; Gupta et al., 1985; Schmiegel et al., immunoassay (Amersham Corp., Arlington Heights, Ill).
1985). Lower sensitivities (40-45%) have been recorded in The data were analysed statistically using the Chi square
advanced colorectal carcinoma (Dukes' C and D) and in test.
gastric carcinoma, but also in various forms of inflammatory With one exception, the serum CA 19-9 concentrations in
bowel disease (Koprowski et al., 1981; Del Villano et al., the 30 normal subjects fell within the limits of the range
1981; Del Villano et al., 1983; Kuusela et al., 1984; Jalanko previously published; range 0-45 uml-1; mean 10.9 uml-I.
et al., 1984; Satake et al., 1985; Gupta et al., 1985; Schmiegel Thirty-seven uml-I was therefore used as the upper limit of
et al., 1985). In addition, CA 19-9 is detectable histo- normal in the present study.
chemically in the corresponding tissues (Atkinson et al.,
1982). Low concentrations of the antigen are present in the HCC Patients Raised CA 19-9 concentrations were present
serum of healthy individuals (Koprowski et al., 1981; Del in the serum of 51.3% (62/121) of the HCC patients. Seven
Villano et al., 1983; Kuusela et al., 1984; Jalanko et al., (5.8%) patients had a value of 37-50uml-1, 15 (12.4%) 51-
1984; Satake et al., 1985; Gupta et al., 1985; Schmiegel et al., I00uml-1 and 40 (33.0%) > 100uml -1.
1985). Serum AFP concentrations were raised (>20ngml-1) in
Like the pancreas, the liver is a foregut derivative, and CA 85.1% (103/121) of the patients. In 14.9% (18/121) of the
19-9 has been demonstrated in normal hepatic tissue patients the value was in the non-diagnostic range (20-
(Atkinson et al., 1982). The possibility that this antigen 500ngml-1), so that 70.2% (85/121) of the patients had a
might be expressed by hepatocellular carcinoma (HCC) diagnostic AFP value (>500ngml-1).
therefore arises. In fact, raised serum values have been Of the 18 patients with a normal serum AFP
described in ten of 36 patients with this tumour, and also in concentration, 12 had an elevated CA 19-9 value. Thus, if
four of 27 patients with benign hepatic diseases (Jalanko et the two tumour markers were used together only 5% of
al., 1984; Satake et al., 1985; Andriulli et al., 1986). The patients (6/121) would have elevation of neither marker. Of
purpose of this study was to measure serum concentrations the 18 patients with a non-diagnostic AFP value, 7 had a
of CA 19-9 in a larger series of patients with HCC and in raised CA 19-9 value. Thus, 9% (11/121) of HCC patients
more patients with those forms of benign hepatic disease would have an equivocal AFP value and a negative CA 19-9
which might be mistaken clinically for HCC, and to compare test.
the sensitivity, specificity and predictive value of CA 19-9
with alpha-foetoprotein (AFP), a proven serum marker of Benign hepatic diseases Serum CA 19-9 values were raised
this tumour (Kew, 1974). in 29.4% (15/51) of the patients with benign hepatic diseases.
One hundred and twenty one southern African Blacks Four patients (7.8%) had a value of 37-50uml-1, 5 (9.8%)
with histologically-proved HCC were included in the study. 51-100uml-1, and 7 (13.7%) >100uml-1. The results in
There were 110 men and 11 women; their ages ranged from the patients with amoebic hepatic abscess were: raised 25%
18 to 82 years (mean 43.8 years). Twenty eight patients with (7/28), 37-50uml-1 10.7% (3/28), 51-100uml-1 7.1%
an amoebic hepatic abscess, 23 with chronic hepatic (2/28), > 100umP1 10.7% (3/28), and in those with chronic
parenchymal disease (chronic active hepatitis, cryptogenic hepatic parenchymal disease: raised 34.8% (8/23), 37-
cirrhosis, alcoholic cirrhosis) and 26 with a wide variety of SOuml-' 4.3% (1/23), 51-100 13.0% (3/23), > lOOumP'
malignant tumours other than HCC (arising from lung, 17.4% (4/23).
colon, stomach, oesophagus, prostate, adrenal, cervix, ovary, Serum AFP concentrations were increased in 8 of the 51
breast, thyroid, kidney; melanoma) were also studied. All of patients (15.7%) with benign hepatic diseases. The two
these patients were Blacks. patients with an abscess (7.1%) who had a raised value had
The normal range of CA 19-9 in serum (<37uml1) has levels of 25 and 54ngml 1, respectively. The raised values in
previously been established in 1020 blood donors (Del the six patients (26.1%) with chronic hepatic parenchymal
____________________________________________ disease were 99, 209, 28, 34, 28 and 21 ngml 1, respectively.
Correspondence: M.C. Kew. The sensitivity, specificity and predictive values of CA 19-
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Table I Comparison between CA 19-9 and alpha-foetoprotein as serum markers of
hepatocellular carcinoma
Alpha-foetoprotein Significance
CA 19-9 (ngml-1) (P)
Sensitivitya 51.3% >20 85.1% <0.001
>500 70.2% <0.01
Specificityb 70.6% >20 84.3% NS
>500 100% NS
Predictive value of a positive testc 80.5% >20 92.8% NS
>500 100% NS
Predictive value of a negative testd 39.9% >20 70.5% <0.05
>500 100% <0.001
Sensitivity true positive
true positive+false negative
bSpecifity * true negative
true negative+false positive
true positive cPredictive value of a positive test=
true positive+false positive
dPredictive value of a negative test= true negative
true negative+false negative'
CA 19-9 of 100 uml- was used, the sensitivity decreased to
33% (P<0.05), the specificity increased to 86% (NS), the
predictive value of a positive test increased to 85.1% (NS),
and the predictive value of a negative test decreased to
35.2% (NS).
Other tumours Raised concentrations of CA 19-9 were
found in 10 of the 26 patients (38.5%) with other tumours (3
with carcinoma of the cervix, 3 with ovarian carcinoma, one
each with carcinoma of the breast, thyroid, and kidney, and
one with a germinoma). Three patients (11.5%) had values
of 37-50uml-1, 4 (15.4%) 51-lOuml-1, and 3 (11.5%)
> 100 um-1.
Small numbers of patients with HCC were included in
three previous analyses of serum concentrations of CA 19-9
in malignant and inflammatory gastrointestinal diseases
(Jalanko et al., 1984; Satake et al., 1985; Andriulli et al.,
1986). Raised values were recorded in one of four patients
studied by Satake et al. (1985) and in five of 14 patients
studied by Andriulli et al. (1986). Jalanko and his colleagues
(1984) found increased concentrations in four of 18 patients
(22%) with HCC, but also in four of 27 with benign hepatic
diseases. The present investigation has shown elevated
CA 19-9 values to be present appreciably more often in
southern African Blacks with HCC. Although this level of
sensitivity as a marker is less than that described in
carcinoma of the pancreas, it is comparable with that
obtained with other gastro-intestinal carcinomas (Koprowski
et al., 1981; Del Villano et al., 1983; Kuusela et al., 1984;
Jalanko et al., 1984; Satake et al., 1985; Gupta et al., 1985;
Schmiegel et al., 1985). The specificity of CA 19-9 in
differentiating HCC from various benign hepatic diseases
with which it might be confused clinically was 71%, with a
predictive value of a positive test of 80.5% and of a negative
test of 39.9%. While these results show CA 19-9 to be a
more useful serum marker of HCC than was suggested by
the earlier data, comparison with AFP shows the latter to be
far more useful in the diagnosis of this tumour.
If the two markers are used together in the diagnosis of
HCC, the number of patients without a raised serum AFP
concentration could be reduced from 15% to 5% and the
number with an equivocal AFP value from 15% to 9%.
If a diagnostic cut-off point for AFP of 500ngml-1 is
used, a sensitivity of 70% is still obtained in southern
African Blacks with HCC and the specificity and predictive
values of positive and negative tests increase to 100%. The
question whether the specificity and predictive value of
CA 19-9 could similarly be improved by using a diagnostic
cut-off level of 100uml-1 was addressed. At this level, the
sensitivity decreases to 33% while the increase in specificity
and the predictive value of a positive test do not reach
statistical significance; the predictive value of a negative test
remains low (35%).
Indirect confirmation of our finding and that of previous
workers that CA 19-9 is frequently not expressed by HCC is
provided by the observation of Atkinson et al. (1982) that
only one of 11 HCCs examined with immunoperoxidase
staining was positive for CA 19-9.
Our finding of raised serum concentrations of CA 19-9 in
patients with a variety of non-gastrointestinal tumours
confirms the observation of Gupta et al. (1985) that CA 19-9
is not specific for gastrointestinal tumours.
In support of the observation of Jalanko et al. (1984), we
too found elevated serum concentrations of CA 19-9 in
patients with inflammatory disease of the liver. The reason
why this antigen is expressed in inflammatory diseases of the
liver (acute and chronic hepatic parenchymal disease and
amoebic hepatic abscesses) is not known. Other tumour-
related antigens, such as tissue polypeptide antigen, may also
be found in high concentration in the serum of patients with
inflammatory hepatic disease (Kew & Berger, 1986). One
possible explanation for these findings is that these antigens
can be expressed by regenerating hepatocytes as well as by
malignant hepatocytes.
The authors are indebted to Centocor Co. for providing the radio-
immunoassay kits for measuring CA 19-9.
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